News Story: Full Text
Sponsored By
Medicenna Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Researchers identify vulnerability for glioblastoma subtypes

Al's Comment:

 This type of research is the key to finding the cure.  All of the treatments that have failed phase 2 and 3 trials should be retested to try to figure out why there was enough success in the phase 1 trial to justify the phase 2, then having the subsequent trial fail.  Most likely there is a subtype of tumor that IS sensitive to the treatment.  


Posted on: 12/02/2017

Researchers identify vulnerability for glioblastoma subtypes

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites



Musella Foundation For Brain Tumor Research & Information, Inc